Encision (ECIA) 10-Q 14 Feb 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2018	Jan. 31, 2019
Document and Entity Information
Entity Registrant Name	ENCISION INC
Entity Central Index Key	930,775
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		11,558,355
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q3

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Current assets:
Cash and cash equivalents	$ 577,000	$ 114,538
Restricted cash	25,000	25,000
Accounts receivable, net of allowance for doubtful accounts of $20,000 at December 31, 2018 and $20,500 at March 31, 2018	1,024,173	962,639
Inventories, net of reserve for obsolescence of $45,000 at December 31, 2018 and $21,000 at March 31, 2018	1,391,107	1,437,159
Prepaid expenses	129,709	74,830
Total current assets	3,146,989	2,614,166
Equipment, at cost:
Furniture, fixtures and equipment	3,031,950	3,021,968
Accumulated depreciation	(2,792,830)	(2,673,037)
Equipment, net	239,120	348,931
Patents, net of accumulated amortization of $259,621 at December 31, 2018 and $238,571 at March 31, 2018	254,319	270,504
Other assets	18,873	18,873
TOTAL ASSETS	3,659,301	3,252,474
Current liabilities:
Accounts payable	690,457	466,418
Accrued compensation	257,775	257,133
Other accrued liabilities	100,390	284,550
Deferred rent	0	30,384
Total current liabilities	1,048,622	1,038,485
Long-term liability:
Deferred rent	73,690	10,128
Total liabilities	1,122,312	1,048,613
Shareholders' equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding	0	0
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 11,558,355 and 10,683,355 shares issued and outstanding at December 31, 2018 and March 31, 2018, respectively	24,204,546	23,817,912
Accumulated (deficit)	(21,667,557)	(21,614,051)
Total shareholders' equity	2,536,989	2,203,861
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 3,659,301	$ 3,252,474

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 20,000	$ 20,500
Inventories, reserve for obsolescence (in dollars)	45,000	21,000
Accumulated amortization	$ 259,621	$ 238,571
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock and additional paid-in capital, par value	$ 0	$ 0
Common stock and additional paid-in capital, shares authorized	100,000,000	100,000,000
Common stock and additional paid-in capital, shares issued	11,558,355	10,683,355
Common stock and additional paid-in capital, shares outstanding	11,558,355	10,683,355

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
NET REVENUE	$ 2,117,454	$ 2,190,305	$ 6,718,257	$ 6,716,480
COST OF REVENUE	1,054,980	956,687	3,149,620	2,880,101
GROSS PROFIT	1,062,474	1,233,618	3,568,637	3,836,379
OPERATING EXPENSES:
Sales and marketing	645,301	569,802	2,077,522	1,745,121
General and administrative	312,001	368,545	953,968	1,057,810
Research and development	189,353	223,977	542,602	635,165
Total operating expenses	1,146,655	1,162,324	3,574,092	3,438,096
OPERATING INCOME (LOSS)	(84,181)	71,294	(5,454)	398,283
Interest expense, net	(1,837)	(15,343)	(48,476)	(44,165)
Other income (expense), net	1,616	118	424	(400)
Interest expense and other income (expense), net	(221)	(15,225)	(48,052)	(44,565)
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	(84,402)	56,069	(53,506)	353,718
Provision for income taxes	0	0	0	0
NET INCOME (LOSS)	$ (84,402)	$ 56,069	$ (53,506)	$ 353,718
Net income (loss) per share - basic and Diluted	$ (0.01)	$ 0.01	$ 0	$ 0.03
Weighted average shares - basic	10,798,740	10,683,355	10,721,817	10,683,355
Weighted average shares - diluted	10,798,740	10,707,814	10,721,817	10,702,493

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net income (loss)	$ (53,506)	$ 353,718
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	140,843	154,150
Share-based compensation expense	36,634	49,335
(Recovery from) doubtful accounts, net	(500)	(18,500)
(Recovery from) provision for inventory obsolescence, net	24,000	(20,000)
Changes in operating assets and liabilities:
Accounts receivable	(61,034)	123,362
Inventories	22,052	(98,423)
Prepaid expenses and other assets	(54,879)	(82,940)
Accounts payable	224,039	118,869
Accrued compensation and other accrued liabilities	(150,340)	(85,167)
Net cash generated by operating activities	127,309	494,404
Investing activities:
Acquisition of property and equipment	(9,982)	(41,647)
Patent costs	(4,865)	(35,238)
Net cash (used in) investing activities	(14,847)	(76,885)
Financing activities:
Borrowings from (paydowns to) of credit facility, net change	0	(275,055)
Proceeds from the issuance of common stock	350,000	0
Net cash generated by (used in) financing activities	350,000	(275,055)
Net increase in cash, cash equivalents, and restricted cash	462,462	142,464
Cash, cash equivalents, and restricted cash beginning of period	139,538	95,117
Cash, cash equivalents, and restricted cash end of period	$ 602,000	$ 237,581

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	9 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to, and saves lives of, patients undergoing minimally-invasive surgery. We believe that our patented AEM ® We have an accumulated deficit of $21,667,557 at December 31, 2018. A significant portion of our operating funds have been provided by issuances of our common stock and warrants, a line of credit, and the exercise of stock options to purchase our common stock. Should our liquidity be diminished in the future because of operating losses, we may be required to seek additional capital. Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals and surgery centers in the United States.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Basis of Presentation. The accompanying condensed interim financial statements have been prepared, in all material respects, in conformity with the standards of accounting measurements and reflect, in the opinion of management, all adjustments necessary to summarize fairly the financial position and results of operations for such periods in accordance with GAAP. All adjustments are of a normal recurring nature. The results of operations for the most recent interim period are not necessarily indicative of the results to be expected for the full year. Use of Estimates in the Preparation of Financial Statements. Cash and Cash Equivalents. Fair Value of Financial Instruments. Concentration of Credit Risk. We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The net accounts receivable balance at December 31, 2018 of $1,024,173 and at March 31, 2018 of $962,639 included no more than 8% from any one customer. Inventories December 31, 2018 March 31, 2018 Raw materials $ 1,149,562 $ 941,964 Finished goods 286,545 516,195 Total gross inventories 1,436,107 1,458,159 Less reserve for obsolescence (45,000 ) (21,000 ) Total net inventories $ 1,391,107 $ 1,437,159 Property and Equipment Long-Lived Assets. Patents. Income Taxes. Revenue Recognition. Research and Development Expenses Stock-Based Compensation Stock-based compensation expense recognized under ASC 718 for the three and nine months ended December 31, 2018 was $10,890 and $36,634, respectively, and for the three and nine months ended December 31, 2017 was $16,143 and $49,335, respectively, which consisted of stock-based compensation expense related to grants of employee stock options and restricted stock units (“RSUs”). Segment Reporting. Recent Accounting Pronouncements. ASU No. 2014-09 (ASC 606), Revenue from Contracts with Customers became effective for us beginning April 1, 2018, and adopted the new accounting standard using the modified retrospective transition approach. We record revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. We will continue to apply our current business processes, policies, systems and controls to support recognition and disclosure under the new standard. Based on the results of the evaluation, we have determined that the adoption of the new standard presents no material impact on our financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 will be effective for the Company beginning in its first quarter of fiscal year 2020 and early adoption is permitted. The Company is currently evaluating the timing of its adoption and the impact of adopting the new lease standard on its consolidated financial statements. However, the ultimate impact of adopting ASU 2016-02 will depend on the Company's lease portfolio as of the adoption date.

BASIC AND DILUTED INCOME AND LO

BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE	9 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE	We report both basic and diluted net income (loss) per share. Basic net income or loss per common share is computed by dividing net income or loss for the period by the weighted average number of common shares outstanding for the period. Diluted net income or loss per common share is computed by dividing the net income or loss for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. The shares used in the calculation of dilutive potential common shares exclude options and RSUs to purchase shares where the exercise price was greater than the average market price of common shares for the period. The following table presents the calculation of basic and diluted net loss per share: Three Months Ended Nine Months Ended December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 Net income (loss) $ (84,402 ) $ 56,069 $ (53,506 ) $ 353,718 Weighted-average shares — basic 10,798,740 10,683,355 10,721,817 10,683,355 Effect of dilutive potential common shares –– 24,459 –– 19,138 Weighted-average shares — diluted 10,798,740 10,707,814 10,721,817 10,702,493 Net income (loss) per share — basic $ (0.01 ) $ 0.01 $ 0.00 $ 0.03 Net income (loss) per share — diluted $ (0.01 ) $ 0.01 $ 0.00 $ 0.03 Antidilutive employee stock options and RSUs 900,286 988,077 900,286 993,398

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Effective November 9, 2017, we extended our noncancelable lease agreement through July 31, 2024 for our facilities at 6797 Winchester Circle, Boulder, Colorado. The lease includes base rent abatement for the first two months, or $55,583, and $145,000 of leasehold improvements granted by the landlord. At the start of the lease on August 1, 2019, the $145,000 will be recorded on our condensed balance sheets as leasehold improvements and deferred rent. The leasehold improvements will be amortized over the lesser of the lease term or the assets life and the deferred rent will be amortized against rent expense over the lease term. The minimum future lease payment, by fiscal year, as of December 31, 2018 is as follows: Fiscal Year Amount 2019 (3 months remaining) $ 73,397 2020 266,550 2021 343,167 2022 357,667 2023 372,167 2024 386,667 2025 130,500 Total $ 1,930,115 On July 31, 2018, we signed a new line of credit agreement with Bank of America Merrill Lynch. The facility provides for up to $1 million revolving line of credit. The interest rate is a rate per year equal to the LIBOR Daily Floating Rate plus 2.75 percentage points. There is a minimum quarterly EBITDA covenant and a minimum Collateral Coverage ratio of 2. Minimum Collateral Coverage is the ratio of gross accounts receivable plus inventory to the line of credit commitment. Aside from the operating lease, we do not have any material contractual commitments requiring settlement in the future. We are subject to regulation by the United States Food and Drug Administration (“FDA”). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine compliance with these regulations. We believe that we were in substantial compliance with all known regulations at December 31, 2018. FDA inspections are conducted periodically at the discretion of the FDA. Our latest inspection by the FDA occurred in October 2016.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	The provisions of ASC 718-10-55 requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors, including employee stock options and RSUs, based on estimated fair values. The following table summarizes stock-based compensation expense related to employee stock options, RSUs and employee stock purchases for the three and nine months ended December 31, 2018 and 2017, which was allocated as follows: Three Months Ended Nine Months Ended December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 Cost of sales $ 658 $ 539 $ 1,973 $ 1,617 Sales and marketing 1,296 3,420 3,890 10,259 General and administrative 8,275 11,378 28,789 34,134 Research and development 661 806 1,982 3,325 Stock-based compensation expense $ 10,890 $ 16,143 $ 36,634 $ 49,335 Share-based compensation cost for stock options is measured at the grant date, based on the fair value as calculated by the Black-Scholes-Merton ("BSM") option-pricing model. The BSM option-pricing model requires the use of actual employee exercise behavior data and the application of a number of assumptions, including expected volatility, risk-free interest rate and expected dividends. There were 10,000 stock options granted and 119,250 stock options forfeited during the three months ended December 31, 2018. There were 102,000 stock options granted and 209,250 stock options forfeited during the nine months ended December 31, 2018. Share-based compensation cost for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. As of December 31, 2018, $99,000 of total unrecognized compensation costs related to nonvested stock options is expected to be recognized over a period of five years.

RELATED PARTY TRANSACTION

RELATED PARTY TRANSACTION	9 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	We paid consulting fees of $17,681 and $52,726 to an entity owned by one of our directors during the three and nine months ended December 31, 2018, respectively, and $16,840 and $49,029 during the three and nine months ended December 31, 2017, respectively.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	We evaluated all of our activity as of the date the condensed interim financial statements were issued and concluded that no subsequent events have occurred that would require recognition in our financial statements or disclosed in the notes to our condensed interim financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation. The accompanying condensed interim financial statements have been prepared, in all material respects, in conformity with the standards of accounting measurements and reflect, in the opinion of management, all adjustments necessary to summarize fairly the financial position and results of operations for such periods in accordance with GAAP. All adjustments are of a normal recurring nature. The results of operations for the most recent interim period are not necessarily indicative of the results to be expected for the full year.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements.
Cash and Cash Equivalents	Cash and Cash Equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments.
Concentration of Credit Risk	Concentration of Credit Risk. We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The net accounts receivable balance at December 31, 2018 of $1,024,173 and at March 31, 2018 of $962,639 included no more than 8% from any one customer.
Inventories	Inventories December 31, 2018 March 31, 2018 Raw materials $ 1,149,562 $ 941,964 Finished goods 286,545 516,195 Total gross inventories 1,436,107 1,458,159 Less reserve for obsolescence (45,000 ) (21,000 ) Total net inventories $ 1,391,107 $ 1,437,159
Property and Equipment	Property and Equipment
Long-Lived Assets	Long-Lived Assets.
Patents	Patents.
Income Taxes	Income Taxes.
Revenue Recognition	Revenue Recognition.
Research and Development Expenses	Research and Development Expenses
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense recognized under ASC 718 for the three and nine months ended December 31, 2018 was $10,890 and $36,634, respectively, and for the three and nine months ended December 31, 2017 was $16,143 and $49,335, respectively, which consisted of stock-based compensation expense related to grants of employee stock options and restricted stock units (“RSUs”).
Segment Reporting	Segment Reporting.
Recent Accounting Pronouncements	Recent Accounting Pronouncements. ASU No. 2014-09 (ASC 606), Revenue from Contracts with Customers became effective for us beginning April 1, 2018, and adopted the new accounting standard using the modified retrospective transition approach. We record revenue under ASC 606 at a single point in time, when control is transferred to the customer, which is consistent with past practice. We will continue to apply our current business processes, policies, systems and controls to support recognition and disclosure under the new standard. Based on the results of the evaluation, we have determined that the adoption of the new standard presents no material impact on our financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 will be effective for the Company beginning in its first quarter of fiscal year 2020 and early adoption is permitted. The Company is currently evaluating the timing of its adoption and the impact of adopting the new lease standard on its consolidated financial statements. However, the ultimate impact of adopting ASU 2016-02 will depend on the Company's lease portfolio as of the adoption date.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of inventory	December 31, 2018 March 31, 2018 Raw materials $ 1,149,562 $ 941,964 Finished goods 286,545 516,195 Total gross inventories 1,436,107 1,458,159 Less reserve for obsolescence (45,000 ) (21,000 ) Total net inventories $ 1,391,107 $ 1,437,159

BASIC AND DILUTED INCOME AND _2

BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE (Tables)	9 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted net loss per share	Three Months Ended Nine Months Ended December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 Net income (loss) $ (84,402 ) $ 56,069 $ (53,506 ) $ 353,718 Weighted-average shares — basic 10,798,740 10,683,355 10,721,817 10,683,355 Effect of dilutive potential common shares –– 24,459 –– 19,138 Weighted-average shares — diluted 10,798,740 10,707,814 10,721,817 10,702,493 Net income (loss) per share — basic $ (0.01 ) $ 0.01 $ 0.00 $ 0.03 Net income (loss) per share — diluted $ (0.01 ) $ 0.01 $ 0.00 $ 0.03 Antidilutive employee stock options and RSUs 900,286 988,077 900,286 993,398

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of minimum future lease payments, by fiscal year	Fiscal Year Amount 2019 (3 months remaining) $ 73,397 2020 266,550 2021 343,167 2022 357,667 2023 372,167 2024 386,667 2025 130,500 Total $ 1,930,115

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock-based compensation expense related to employee stock options	Three Months Ended Nine Months Ended December 31, 2018 December 31, 2017 December 31, 2018 December 31, 2017 Cost of sales $ 658 $ 539 $ 1,973 $ 1,617 Sales and marketing 1,296 3,420 3,890 10,259 General and administrative 8,275 11,378 28,789 34,134 Research and development 661 806 1,982 3,325 Stock-based compensation expense $ 10,890 $ 16,143 $ 36,634 $ 49,335

ORGANIZATION AND NATURE OF BU_2

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 21,667,557	$ 21,614,051

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2018	Mar. 31, 2018
Inventories
Raw materials	$ 1,149,562	$ 941,964
Finished goods	286,545	516,195
Total gross inventories	1,436,107	1,458,159
Less reserve for obsolescence	(45,000)	(21,000)
Total net inventories	$ 1,391,107	$ 1,437,159

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 31, 2018
Property, Plant and Equipment [Line Items]
Federally insured limit	$ 250,000		$ 250,000
Accounts Receivable	1,024,173		1,024,173		$ 962,639
Stock-based compensation expense	10,890	$ 16,143	36,634	$ 49,335
Unrecognized tax benefits	$ 0		$ 0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets			5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of assets			7 years

BASIC AND DILUTED INCOME AND _3

BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net income (loss)	$ (84,402)	$ 56,069	$ (53,506)	$ 353,718
Weighted-average shares - basic	10,798,740	10,683,355	10,721,817	10,683,355
Effect of dilutive potential common shares	0	24,459	0	19,138
Weighted-average shares - diluted	10,798,740	10,707,814	10,721,817	10,702,493
Net income (loss) per share-basic	$ (0.01)	$ 0.01	$ .00	$ 0.03
Net income (loss) per share-diluted	$ (0.01)	$ 0.01	$ .00	$ 0.03
Antidilutive employee stock options and RSUs	900,286	988,077	900,286	993,398

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2018USD ($)
Minimum future lease payments, by fiscal year
2019 (3 months remaining)	$ 73,397
2,020	266,550
2,021	343,167
2,022	357,667
2,023	372,167
2,024	386,667
2,025	130,500
Total	$ 1,930,115

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Dec. 31, 2018USD ($)
Commitments And Contingencies Details Narrative
Amount of borrowings	$ 0
Amount available to borrow	$ 1,000,000

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 10,890	$ 16,143	$ 36,634	$ 49,335
Cost Of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	658	539	1,973	1,617
Selling And Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	1,296	3,420	3,890	10,259
General And Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	8,275	11,378	28,789	34,134
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 661	$ 806	$ 1,982	$ 3,325

SHARE-BASED COMPENSATION (Det_2

SHARE-BASED COMPENSATION (Details Narrative)	3 Months Ended	9 Months Ended
	Dec. 31, 2018USD ($)shares	Dec. 31, 2018USD ($)shares
Share-based Compensation Details Narrative
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants	10,000	102,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited	119,250	209,250
Unrecognized compensation costs related to nonvested stock options | $	$ 99,000	$ 99,000

RELATED PARTY TRANSACTION (Deta

RELATED PARTY TRANSACTION (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Director [Member]
Related Party Transaction [Line Items]
Consulting fees paid	$ 17,681	$ 16,840	$ 52,726	$ 49,029